Leqembi, Formerly Lecanemab, Gets FDA Approval to Treat Alzheimer's | Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Biogen is discontinuing development and commercialization of its controversial Alzheimer's treatment Aduhelm to focus its efforts on Leqembi.| Alzheimer's News Today
One-year data from a Phase 2 trial's extension showed safe and rapid, sustained drops in beta-amyloid levels in early stage patients.| Alzheimer's News Today
The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S. policies.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
Under-the-skin injections worked better in trial than the approved Leqembi formulation in clearing harmful amyloid plaques in Alzheimer's.| Alzheimer's News Today
Just-released full data from the Phase 3 Clarity AD trial show lecanemab can significantly slow dementia in early-onset Alzheimer’s patients.| Alzheimer's News Today
Donanemab slowed cognitive, functional ability declines in early Alzheimer’s disease, according to top-line data from a Phase 3 trial.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today
Eisai has started a rolling application seeking U.S. FDA approval of an under-the-skin injection version of Leqembi for early Alzheimer’s.| Alzheimer's News Today
Eisai is seeking FDA approval of a monthly maintenance IV regimen of Leqembi for people with early Alzheimer’s disease.| Alzheimer's News Today
